Risk Factors Associated with Malignant Transformation of Astrocytoma: Competing Risk Regression Analysis

Background: Malignant transformation (MT) of low-grade astrocytoma (LGA) triggers a poor prognosis in benign tumors. Currently, factors associated with MT of LGA have been inconclusive. The present study aims to explore the risk factors predicting LGA progressively differentiation to malignant astrocytoma. Materials and Methods: The study design was a retrospective cohort study of medical record reviews of patients with LGA. Using the Fire and Grey method, the competing risk regression analysis was performed to identify factors associated with MT, using both univariate and multivariable analyses. Hence, the survival curves of the cumulative incidence of MT of each covariate were constructed following the final model. Results: Ninety patients with LGA were included in the analysis, and MT was observed in 14.4% of cases in the present study. For MT, 53.8% of patients with MT transformed to glioblastoma, while 46.2% differentiated to anaplastic astrocytoma. Factors associated with MT included supratentorial tumor (subdistribution hazard ratio [SHR] 4.54, 95% CI 1.08–19.10), midline shift >1 cm (SHR 8.25, 95% CI 2.18–31.21), nontotal resection as follows: Subtotal resection (SHR 5.35, 95% CI 1.07–26.82), partial resection (SHR 10.90, 95% CI 3.13–37.90), and biopsy (SHR 11.10, 95% CI 2.88–42.52). Conclusion: MT in patients with LGA significantly changed the natural history of the disease to an unfavorable prognosis. Analysis of patients' clinical characteristics from the present study identified supratentorial LGA, a midline shift more than 1 cm, and extent of resection as risk factors associated with MT. The more extent of resection would significantly help to decrease tumor burden and MT. In addition, future molecular research efforts are warranted to explain the pathogenesis of MT.

[1]  P. Tanvejsilp,et al.  The clinical characteristics and prognostic factors of multiple lesions in glioblastomas , 2020, Clinical Neurology and Neurosurgery.

[2]  K. Kawai,et al.  How definitive treatment affects the rupture rate of unruptured cerebral aneurysms: a competing risk survival analysis. , 2020, Journal of neurosurgery.

[3]  Thara Tunthanathip,et al.  Factors associated with the extent of resection of glioblastoma , 2020, Precision Cancer Medicine.

[4]  S. Sangkhathat,et al.  Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching , 2020, Clinical Neurology and Neurosurgery.

[5]  U. Intusoma,et al.  Prognostic Factors and Nomogram Predicting Survival in Diffuse Astrocytoma , 2020, Journal of Neurosciences in Rural Practice.

[6]  Thara Tunthanathip,et al.  No association between isocitrate dehydrogenase 1 mutation and increased survival of glioblastoma: A meta-analysis , 2020 .

[7]  S. Sae-heng,et al.  The First Awake Craniotomy for Eloquent Glioblastoma in Southern Thailand , 2019, Journal of Health Science and Medical Research.

[8]  Jennifer S. Yu,et al.  Malignant Transformation of Molecularly Classified Adult Low Grade Glioma. , 2019, International journal of radiation oncology, biology, physics.

[9]  M. Resche-Rigon,et al.  Intracranial WHO grade I meningioma: a competing risk analysis of progression and disease-specific survival , 2019, Acta Neurochirurgica.

[10]  T. Oearsakul,et al.  Diagnostic Yield and Complication of Frameless Stereotactic Brain Biopsy , 2019, Journal of Neurosciences in Rural Practice.

[11]  Jong-Hee Chang,et al.  Recurrence patterns after maximal surgical resection and postoperative radiotherapy in anaplastic gliomas according to the new 2016 WHO classification , 2018, Scientific Reports.

[12]  Jennifer S. Yu,et al.  Risk Factors for Malignant Transformation of Low-Grade Glioma. , 2017, International journal of radiation oncology, biology, physics.

[13]  Anshu Gupta,et al.  A Simplified Overview of World Health Organization Classification Update of Central Nervous System Tumors 2016 , 2017, Journal of Neurosciences in Rural Practice.

[14]  Jason P Fine,et al.  Practical recommendations for reporting Fine‐Gray model analyses for competing risk data , 2017, Statistics in medicine.

[15]  Örjan Smedby,et al.  Quantitative MRI for analysis of peritumoral edema in malignant gliomas , 2017, PloS one.

[16]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[17]  Jessica A. Tang,et al.  Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis. , 2016, Neuro-oncology practice.

[18]  Inho Park,et al.  Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas , 2015, Oncotarget.

[19]  Jayesh Sardhara,et al.  Multiple glioblastomas: Are they different from their solitary counterparts? , 2015, Asian journal of neurosurgery.

[20]  Guo-shi Lin,et al.  Peritumoral edema on magnetic resonance imaging predicts a poor clinical outcome in malignant glioma , 2015, Oncology letters.

[21]  R. Sangthong,et al.  Free survival time of recurrence and malignant transformation and associated factors in patients with supratentorial low-grade gliomas. , 2013, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[22]  A. Laxton,et al.  Competing Risk Analysis of Neurologic versus Nonneurologic Death in Patients Undergoing Radiosurgical Salvage After Whole-Brain Radiation Therapy Failure: Who Actually Dies of Their Brain Metastases? , 2013, International journal of radiation oncology, biology, physics.

[23]  Zhi-xiong Lin Glioma-related edema: new insight into molecular mechanisms and their clinical implications , 2013, Chinese journal of cancer.

[24]  B. Bobek-Billewicz,et al.  The assessment of prognostic factors in surgical treatment of low-grade gliomas: A prospective study , 2012, Clinical Neurology and Neurosurgery.

[25]  A. Baghestani,et al.  How to control confounding effects by statistical analysis , 2012, Gastroenterology and hepatology from bed to bench.

[26]  M. Berger,et al.  GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME , 2008, Neurosurgery.

[27]  D. Ellison,et al.  Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  John P Klein,et al.  Modelling competing risks in cancer studies , 2006, Statistics in medicine.

[29]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[30]  A. Sav,et al.  Effect of surgery on tumor progression and malignant degeneration in hemispheric diffuse low-grade astrocytomas , 2002, Journal of Clinical Neuroscience.

[31]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[32]  M. Faist,et al.  Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas , 1997, Cancer.

[33]  D. Schoenfeld,et al.  Sample-size formula for the proportional-hazards regression model. , 1983, Biometrics.

[34]  Thara Tunthanathip,et al.  Glioblastoma Multiforme Associated with Arteriovenous Malformation: A Case Report and Literature Review , 2020, Annals of Indian Academy of Neurology.

[35]  R. Gutierrez Competing-risks regression , 2010 .

[36]  M. McGirt,et al.  Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. , 2010, Journal of neurosurgery.

[37]  B. Iliescu,et al.  Malignant transformation of low grade gliomas into glioblastoma a series of 10 cases and review of the literature , 2010 .